Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
Autor: | Luis Jodar, John M McLaughlin, Vincenza Snow, Aaron Curry, Oliver Will, Farid Khan, Raul E Isturiz, David L. Swerdlow |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
Pediatrics medicine.medical_specialty Race ethnicity Vaccination Coverage 030231 tropical medicine Immunology Disparities Pneumococcal conjugate vaccine Pneumococcal Infections Pneumococcal Vaccines 03 medical and health sciences 0302 clinical medicine medicine Ethnicity Immunology and Allergy Humans 030212 general & internal medicine Healthcare Disparities Aged Pharmacology Aged 80 and over Vaccines Conjugate business.industry Age Factors race/ethnicity Antibodies Bacterial United States socioeconomic status (SES) Cross-Sectional Studies Streptococcus pneumoniae Socioeconomic Factors 13-valent pneumococcal conjugate vaccine (PCV13) Pneumococcal vaccination Female business pneumococcal vaccination medicine.drug Research Paper |
Zdroj: | Human Vaccines & Immunotherapeutics |
ISSN: | 2164-554X |
Popis: | Background: In September 2014, 13-valent pneumococcal conjugate vaccine (PCV13) was universally recommended for all US adults aged ≥65 years. Adult PCV13 coverage, including whether disparities in uptake exist, however, is not well-described. Methods: We used a monthly series of cross-sectional analyses of administrative medical and prescription claims data collected by IQVIA and linked to sociodemographic data collected by Experian to estimate overall and subpopulation-level uptake of PCV13 among US adults aged ≥65 years. Results: Among adults aged ≥65 years, 43.3% received PCV13 by the end of November 2017. Race/ethnicity, annual household income, education status, and neighborhood urbanicity were strongly related to PCV13 uptake among adults aged ≥65 years. Lower uptake of PCV13 was observed for non-Hispanic black (36.3%) and Hispanic (30.0%) adults (vs 45.6% for non-Hispanic whites, P |
Databáze: | OpenAIRE |
Externí odkaz: |